A5057773523- Lung Cancer Treatments and Mutations
- Colorectal Cancer Treatments and Studies
- Lung Cancer Research Studies
- Cancer Immunotherapy and Biomarkers
- Lung Cancer Diagnosis and Treatment
- Cytokine Signaling Pathways and Interactions
- Neuroendocrine Tumor Research Advances
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Glycosylation and Glycoproteins Research
- Peptidase Inhibition and Analysis
- Asthma and respiratory diseases
- Gastric Cancer Management and Outcomes
- Tracheal and airway disorders
- Cardiac tumors and thrombi
- Hepatocellular Carcinoma Treatment and Prognosis
- Chemical Reactions and Isotopes
- Metastasis and carcinoma case studies
- Immune Cell Function and Interaction
- Head and Neck Cancer Studies
- Vascular Anomalies and Treatments
- Cancer Genomics and Diagnostics
- Sarcoma Diagnosis and Treatment
- Chronic Obstructive Pulmonary Disease (COPD) Research
- Cancer therapeutics and mechanisms
- Lymphoma Diagnosis and Treatment
Obihiro Kosei General Hospital
2015-2024
Obihiro National Hospital
2013-2022
Neurology, Inc
2016
Health First
2014
Hokkaido University
1997-2004
Sapporo National Hospital
1997
Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor combined with cytotoxic chemotherapy is highly effective for the treatment of advanced non-small-cell lung cancer (NSCLC) EGFR mutations; however, little known about efficacy and safety this combination compared that standard therapy EGFR- inhibitors alone.We randomly assigned 345 patients newly diagnosed metastatic NSCLC mutations to gefitinib carboplatin plus pemetrexed or alone. Progression-free survival (PFS), PFS2,...
9005 Background: Although EGFR-TKI alone has been a standard first-line treatment for pts with advanced NSCLC EGFR mutations, our phase II study (NEJ005) showed promising efficacy of GCP. NEJ009, an open-label, randomized III study, was conducted to evaluate the superiority GCP vs G in progression-free survival (PFS), PFS2, and overall (OS). Methods: Pts newly diagnosed stage III/IV/ recurrent harboring activating mutations (exon 19 deletion or exon 21 L858R) were 1:1 250 mg PO QD (G 250mg...
Immune-checkpoint inhibitors (ICIs) are effective against advanced non-small cell lung cancer (NSCLC). However, whether the efficacy and safety of ICI treatment in elderly patients similar to those younger is unclear. This study was designed address this question.We enrolled who received monotherapy Japan between December 2015 2017; ≥75 years age comprised group. We compared with explored prognostic factors patients.We 676 patients; 137 (20.3%) were assigned The median groups 78 (range,...
Delta-like protein 3 (DLL3) is a Notch ligand that has an important role in the tumorigenesis of small cell lung cancer (SCLC). Recently, rovalpituzumab tesirine (Rova-T), DLL3-targeted antibody-drug conjugate, been developed for treating SCLC. DLL3 transcriptional target achaete-scute homolog-1 (ASCL1) transcription factor, which involved pulmonary neuroendocrine development. However, relationship between and/or ASCL1 expression and clinical features SCLC remains unknown, especially...
Smoking may have multifactorial effects on asthma phenotypes, particularly in severe asthma. Cluster analysis has been applied to explore novel which are not based any a priori hypotheses.To phenotypes by cluster when including smoking patients with asthma.We recruited total of 127 subjects asthma, 59 current or ex-smokers, from our university hospital and its 29 affiliated hospitals/pulmonary clinics. Clinical variables obtained during 2-day stay were used for analysis. After clustering...
Abstract Background and objective Pulmonary hypertension ( PH ) is often associated with respiratory diseases, but only a small number of patients present severe defined as mean pulmonary arterial pressure ≥ 35 mm Hg. We here conducted multicenter, retrospective study diseases R‐PH to reveal their demographics, treatment, prognosis determinants prognosis. Methods From 101 collected by postal survey at the first stage, 70 four major (chronic obstructive disease COPD ), combined fibrosis...
<p>Supplementary Figure S4. OS according to number of whole irAEs Abbreviations: CI, confidence interval; HR, hazard ratio; irAE, immune-related adverse event; NE, not evaluable; NR, reached; OS, overall survival</p>
<p>Supplementary Figure S1. PFS according to the grade of irAE (A) 4 weeks landmark (B) 8 One event with undetermined was excluded from analysis. Abbreviations: CI, confidence interval; HR, hazard ratio; irAE, immune-related adverse event; PFS, progression-free survival</p>
<p>Supplementary Figure S2. PFS of irAE skin or endocrine disorders (A) according to the onset (B) grade One event with undetermined was excluded from analysis grade. Abbreviations: CI, confidence interval; HR, hazard ratio; irAE, immune-related adverse event; PFS, progression-free survival </p>
<p>Supplementary Figure S3. PFS of irAE other than skin or endocrine disorders (A) according to the onset (B) grade One event with undetermined was excluded from analysis grade. Abbreviations: CI, confidence interval; HR, hazard ratio; irAE, immune-related adverse event; PFS, progression-free survival</p>
Objective: Recent studies have shown that theophylline may exert anti‐inflammatory effects on neutrophils. We undertook to assess the effect of airway inflammation in COPD. Methodology: performed a 4‐week randomized double‐blind, placebo‐controlled study 11 theophylline‐naive patients with mild moderate After 1‐week run‐in period, six subjects were administered 400 mg/day (Theodur; Nikken Chemicals Co. Ltd, Tokyo, Japan) for 4 weeks, while five placebo. Induced sputum was obtained before and...
Delta-like 1 homolog (DLK1) is a non-canonical Notch ligand known to be expressed in several cancers but whose role lung cancer not yet fully understood. We sought confirm DLK1 expression small-cell (SCLC) and non-small-cell (NSCLC), examine DLK1's clinical significance. Furthermore, we examined the possible utility of as novel target radioimmunotherapy (RIT).We retrospectively assessed correlation between features by immunohistochemistry resected specimens from 112 patients with SCLC 101...
Intravascular lymphomatosis is a rare lymphoma presenting variety of symptoms due to proliferation tumour cells within blood vessels in the brain, skin and other organs. This disease generally considered be highly malignant, but relatively susceptible combined chemotherapy, when diagnosed early stage. We describe case intravascular lymphomatosis, with diffuse interstitial shadows on chest radiographic image, which could by transbronchial lung biopsy. The patient showed good response...
// Hajime Kikuchi 1 , Jun Sakakibara-Konishi Megumi Furuta Hiroshi Yokouchi 2 Nishihara 3 Shigeo Yamazaki 4 Hidetaka Uramoto 5, 6 Fumihiro Tanaka 5 Masao Harada 7 Kenji Akie 8 Fumiko Sugaya 9 Yuka Fujita 10 Kei Takamura 11 Tetsuya Kojima 12 Toshiyuki 13 Mitsunori Higuchi 14, 15 Osamu Honjo 9, 16 Yoshinori Minami 17 Naomi Watanabe 18 Satoshi Oizumi 1, Hiroyuki Suzuki Takashi Ishida 2, 19 Hirotoshi Dosaka-Akita 20 Isobe Mitsuru Munakata Masaharu Nishimura Department of Medicine, Hokkaido...
The herbal medicine rikkunshito has the potential to improve chemotherapy-induced nausea and vomiting (CINV) by stimulating ghrelin secretion. We aimed evaluate efficacy safety of in preventing CINV for patients with lung cancer. Two separate prospective, randomized, phase II parallel design studies were conducted Fifty-eight 62 scheduled receive highly emetogenic chemotherapy (HEC) moderately (MEC), respectively, randomized 1:1 either standard antiemetic therapy accordance international...